| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Procaine adverse reaction |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Proxymetacaine adverse reaction |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate+kaolin 10mg/3g/10mL mixture |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Kaolin and morphine mixture BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Paracetamol+codeine phosphate 500mg/30mg/sachet powder (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 60 mg and paracetamol 1 g effervescent powder for oral suspension sachet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely codeine phosphate 13.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 12.8 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing kaolin and morphine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing magnesium sulfate in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to nitrous oxide |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction caused by cyclopropane (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction caused by surface and infiltration anesthetic (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction caused by tetracaine (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to peripheral nerve and plexus blocking anaesthetic |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to spinal anesthetic |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to hallucinogen |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction caused by cannabis (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction caused by lysergide (disorder) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to mescaline |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to psilocin |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to psilocybin |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Drug reaction to anticonvulsant (finding) |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Acetaminophen + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to other anticonvulsant |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to anticonvulsants NOS |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to antiparkinsonism drugs NOS |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to anticonvulsant and antiparkinsonism drugs NOS |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to other gaseous anesthetics |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to gaseous anesthetic NOS |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to intravenous anesthetic NOS |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to other general anesthetics |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to local anesthetics NOS |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to other local anesthetics |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to hallucinogen NOS |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to other psychotropic agent |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to psychotropic agent NOS |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Drug reaction - CNS drug NOS |
Causative agent (attribute) |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| médicament pour le système nerveux central |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| NMDA receptor antagonist-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Buprenorphine hydrochloride + naloxone hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Buprenorphine hydrochloride 2mg + naloxone hydrochloride 0.5mg sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Buprenorphine hydrochloride 8mg + naloxone hydrochloride 2mg sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Morphine sulfate 30mg/30mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Galantamine 4mg/mL s/f oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ropinirole 250micrograms+500micrograms+1000micrograms tablet starter pack |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ropinirole 0.5mg+1mg+2mg tablet follow-on pack |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Morphine sulfate 10mg/mL injection solution prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Buprenorphine 35micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Buprenorphine 52.5micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Buprenorphine 70micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Oxycodone hydrochloride 5mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Drugs used in neuropathic pain |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Oxycodone hydrochloride 10mg/mL injection solution 2mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Oxycodone hydrochloride 10mg/mL injection solution 1mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Bupivacaine hydrochloride+fentanyl |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Bupivacaine hydrochloride+fentanyl 0.1%/2micrograms/mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rivastigmine (as rivastigmine tartrate) 2 mg/mL oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin+papaveretum 500mg/10mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Papaveretum 10mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Papaveretum 20mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lithium AND/OR lithium compound |
Is a |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Caffeine |
Is a |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theobromine (substance) |
Is a |
True |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing levomethadyl (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing levomethadyl acetate hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing chlorphenamine polistirex and hydrocodone polistirex |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocodone polistirex 10mg/chlorpheniremine polistirex 8mg per 5mL oral m/r suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methadone hydrochloride 25mg/mL injection 2mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methadone hydrochloride 50mg/mL injection 1mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and codeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing guaifenesin and hydrocodone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing pethidine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocodone- and phenylephrine-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing codeine and phenylephrine and promethazine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing codeine and guaifenesin and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Morphine sulfate 10mg/mL extended release liposome injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing chlorphenamine and hydrocodone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing chlorphenamine and codeine and phenylephrine and potassium iodide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing codeine and guaifenesin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Chlorphenamine- and hydrocodone- and pseudoephedrine-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing hydrocodone bitartrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing chlorphenamine and guaifenesin and hydrocodone and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Morphine sulfate + dextrose |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing nalbuphine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin + oxycodone hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing hydrocodone and phenylpropanolamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing propoxyphene hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing propoxyphene napsylate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Chlorphenamine- and codeine- and pseudoephedrine-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ropinirole hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine- and paracetamol-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin 325 mg and codeine 30 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely aspirin 325 milligram and codeine 60 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing dezocine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dezocine 5mg/mL injection solution 1mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dezocine 10mg/mL injection solution 1mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dezocine 15mg/mL injection solution 1mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]